Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN14615267
ISRCTN14615267
Completed
未知

A randomised, double-blind, cross-over, placebo controlled clinical trial to demonstrate the effectiveness of a product designed to protect against establishment of a head louse infestation.

Oystershell NV0 sites70 target enrollmentApril 30, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Oystershell NV
Enrollment
70
Status
Completed
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 30, 2015
End Date
August 30, 2015
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Potential participants attending school with no upper age limit, although they must be the youngest qualifying member of the household
  • •2\. Potential participants who upon examination, are confirmed to be at risk of infestation with head lice
  • •3\. Potential participants who give written informed consent, or if the participant is under 16 years of age whose parent/guardian gives written informed consent to participate in the study
  • •4\. Potential participants who will be available for home visits by MEC study team members over the 13 weeks of the study

Exclusion Criteria

  • •1\. Potential participants with a known sensitivity to sesame, sesame oil, any of the ingredients in Elimax shampoo, Elimax lotion or the placebo shampoo preparations
  • •2\. Potential participants with a secondary bacterial infection of the scalp (e.g. impetigo) or who have a long term scalp condition (e.g. psoriasis of the scalp)
  • •3\. Pregnant or nursing mothers
  • •4\. Potential participants who have participated in another clinical study within 1 month before entry to this study
  • •5\. Potential participants who have already participated in this clinical study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Can we prevent head lice?Head louse infestationInfections and InfestationsHead-louse infestation
ISRCTN09524995Thornton & Ross Ltd (UK)68
Active, not recruiting
Phase 1
A study to learn how safe BAY 2395840 is and how well it works in participants who have diabetic nerve pain.europathic pain associated with diabetic peripheral neuropathyMedDRA version: 21.1Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2021-001392-17-ESBayer AG80
Active, not recruiting
Phase 1
A study to learn how safe BAY 2395840 is and how well it works in participants who have diabetic nerve paieuropathic pain associated with diabetic peripheral neuropathyMedDRA version: 21.1Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2021-001392-17-SKBayer AG75
Active, not recruiting
Phase 1
A study to learn how safe BAY 2395840 is and how well it works in participants who have diabetic nerve pain.europathic pain associated with diabetic peripheral neuropathyMedDRA version: 21.1Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2021-001392-17-DEBayer AG80
Active, not recruiting
Phase 1
A study to learn how safe BAY 2395840 is and how well it works in participants who have diabetic nerve pain.
EUCTR2021-001392-17-HUBayer AG75